Agilent Technologies and National University of Ireland Open Biological Mass Spectrometry Facility
News Feb 09, 2009
Agilent Technologies Inc. and the National University of Ireland (NUI), Galway, have announced the opening of a Biological Mass Spectrometry Facility on the NUI Galway campus. The facility is fully equipped with the latest accurate-mass quadrupole time-of-flight (Q-TOF) and triple quadrupole (QQQ) mass spectrometer platforms from Agilent.
The facility primarily focuses on functional genomics, proteomics, lipidomics and metabolomics research. As part of the collaboration, NUI Galway will provide application notes and data for key applications using the Agilent Q-TOF and QQQ platforms. The facility will also be used to showcase new instruments to Agilent customers and to run samples for demonstration purposes.
“The opening of this facility is a continuation of Agilent’s drive to be a key technology partner for innovative research in academia,” said Gustavo Salem, general manager for Agilent’s LC/MS business. “NUI Galway has some of the top primary investigators in Europe. We look forward to working closely with them to further their breakthrough research in the fields of metabolomics and proteomics.”
“NUI Galway has recently made a substantial commitment to increase its capability in mass spectrometry, in particular targeting life science research,” said Professor Terry Smith, vice president for Research, NUI Galway. “With our recent investment, sponsored by IDA, SFI and Agilent Ireland, NUI Galway now has this capability.”
Primary investigators Dr. David Finn, Dr. Niclas Karlsson and Brendan Harhen will run the mass spectrometers at the facility.
The collaboration between NUI Galway and Agilent is a result of Agilent’s Academia Program, which facilitates collaborations with universities around the world. The program assists universities with teaching, materials and creating research partnerships.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE